Payment overview · 2025
General Payments
$3,045.88
52 reported records · 9 companies
Healthcare provider profile · identity verified
David W Frazier, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · GREENVILLE, NC · NPI 1114076395
Verified facts
What the public records show
CMS Open Payments records show David W Frazier, MD received $3,045.88 in general payments during 2025 across 52 reported records.
BIOTRONIK INC. accounted for 69.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 918 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $2,120.16 | 69.6% | 22 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$297.96 | 9.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $294.33 | 9.7% | 12 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $210.57 | 6.9% | 6 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $51.64 | 1.7% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $21.43 | 0.7% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $18.93 | 0.6% | 1 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.40 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.46 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,561.10 | 3 |
| Food and Beverage | $1,484.78 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $749.07 | 3 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $657.10 | 8 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $237.98 | 4 | 2025 |
Source payment records
|
|||||
| Selectra Normalized: selectra |
Device | BIOTRONIK INC. | $170.03 | 2 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $164.66 | 8 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $128.93 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $128.69 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $59.98 | 2 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $51.64 | 2 | 2025 |
Source payment records
|
|||||
| AGILIS Normalized: agilis |
Device | Abbott Laboratories | $35.60 | 2 | 2025 |
Source payment records
|
|||||
| SQ-RX PULSE GENERATOR Normalized: sq rx pulse generator |
Device | Boston Scientific Corporation | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| AGILIS HISPRO Normalized: agilis hispro |
Device | Abbott Laboratories | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| ACUITY Steerable Normalized: acuity steerable |
Device | Boston Scientific Corporation | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| COOL POINT Normalized: cool point |
Device | Abbott Laboratories | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| TACTICATH ABLATION CATHETER, SENSOR ENABLED Normalized: tacticath ablation catheter sensor enabled |
Device | Abbott Laboratories | $22.02 | 2 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $19.78 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | Abbott Laboratories | $12.69 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $12.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 918 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
918 | 220 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 918 | 220 |
| Ranolazine Er | Ranolazine | 457 | 124 |
| Sotalol | Sotalol Hcl | 408 | 106 |
| Flecainide Acetate | Flecainide Acetate | 388 | 125 |
| Amiodarone Hcl | Amiodarone Hcl | 372 | 107 |
| Nebivolol Hcl | Nebivolol Hcl | 316 | 90 |
| Multaq | Dronedarone Hcl | 304 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 97 |
| Xarelto | Rivaroxaban | 232 | 55 |
| Propafenone Hcl | Propafenone Hcl | 213 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 66 |
| Potassium Chloride | Potassium Chloride | 197 | 55 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 193 | 55 |
| Dofetilide | Dofetilide | 147 | 31 |
| Digoxin | Digoxin | 99 | 31 |
| Carvedilol | Carvedilol | 96 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 91 | 33 |
| Furosemide | Furosemide | 85 | 29 |
| Valsartan | Valsartan | 83 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 63 |
| Ramipril | Ramipril | 66 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 22 |
| Losartan Potassium | Losartan Potassium | 56 | 19 |
| Colchicine | Colchicine | 54 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 14 |
| Nitroglycerin | Nitroglycerin | 48 | 30 |
| Droxidopa | Droxidopa | 47 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | 28 |
| Atenolol | Atenolol | 43 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 42 |
| Midodrine Hcl | Midodrine Hcl | 38 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 34 | 14 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Lisinopril | Lisinopril | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 29 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Quinidine Sulfate | Quinidine Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,045.88 · 52 records | BIOTRONIK INC. | ACUITY Steerable, AFFERA MAPPING SYSTEM, AGILIS, AGILIS HISPRO, AMVIA EDGE, Acticor 7 VR-T DX, Assure WCD, BIOMONITOR, CARDIVA VASCADE MVP XL VVCS 10-12F, COOL POINT, ELIQUIS, ENSITE, ENSITE PRECISION, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, FARAPULSE, General - Therapies, NA, PERCLOSE PROSTYLE, PULSESELECT, SQ-RX PULSE GENERATOR, Selectra, Sotalol Hydrochloride, TACTICATH ABLATION CATHETER, SENSOR ENABLED | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error